Vaxart starts Ph1 oral vax trial

San Francisco-based Vaxart has started dosing patients in its first Phase I trial using its oral vaccine platform. The study uses an H5N1 flu vaccine, but the platform, if effective, could be used with several other vaccines. The trial will take place in the U.S. Vaxart release

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.